Clinical trials: Histological Type of Neoplasm
Myomas, Ovary Cysts
The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions
The purpose of this study was to determine whether the new crosslinked hyaluronan hydrogel was safe to use, and was effective for the prevention/reduction of adhesion formation following gynecological surgery
- Conditions
- Myomas, Ovary Cysts, Endometriotic Cysts, Adhesions
- Trial name
- BAP (NCT02166554)
- Testing
- Saline, Cross-linked Hyaluronan Hydrogel
- Where
- 7 sites in China
- Volunteers
- 216 people
- Sponsor
- BioRegen Biomedical (Changzhou) Co., Ltd
Multiple Myeloma
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
This multicenter, open-label trial will randomize participants with multiple myeloma to a regimen of ibandronate or zoledronate in order to compare the incidence of nephrotoxicity, measured as creatinine clearance (CrCl)…
- Trial name
- COMPARE (NCT02739594)
- Testing
- Ibandronate, Zoledronate
- Where
- 56 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
Hodgkin Lymphoma
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
The main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks.
- Trial name
- BV-MAZOVIA (NCT05100056)
- Testing
- No Intervention
- Where
- 13 sites in Poland
- Volunteers
- 70 people
- Sponsor
- Takeda
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Endometrial Neoplasms, Neoplasms
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386…
- Conditions
- Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
- Trial name
- NCT04008797
- Testing
- E7386, Lenvatinib, Doxorubicin
- Where
- 106 sites in United States, Canada and 8 more
- Volunteers
- 301 people
- Sponsor
- Eisai Inc.
Large B-cell Lymphoma, Follicular Lymphoma
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
- Trial name
- NCT05776160
- Testing
- Axicabtagene Ciloleucel
- Where
- 128 sites in United States, Japan
- Sponsor
- Kite, A Gilead Company
Head and Neck Cancer
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003182
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hope Cancer Institute, Inc.
B-cell Non-Hodgkin's Lymphoma
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL.
- Trial name
- NCT05436223
- Testing
- Human CD19Targeted T Cells Injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Malignant Melanoma, Neoplasms
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
This open-label, multicenter, parallel study will evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of phenprocoumon in patients with BRAFV600 mutation-positive metastatic malignancies.
- Trial name
- NCT01849666
- Testing
- phenprocoumon, vemurafenib
- Where
- 17 sites in Belgium, Finland and 3 more
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Stroke, Meningioma
Robot-Assisted Neurovascular Intervention
Patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.
- Conditions
- Stroke, Meningioma, Neurovascular Disorder
- Trial name
- NCT06752096
- Testing
- cerebral angiography, arterial embolization, thrombectomy, Cerebral angiogram using robotic device, Meningioma embolization using robotic device.
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Navigantis Inc.
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Glioblastoma Multiforme, Adult
The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme.
- Trial name
- NCT05333588
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Relapsed or Refractory Multiple Myeloma
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or…
- Trial name
- NCT07312188
- Testing
- F182112+P, F182112+CD38
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Hodgkin Lymphoma
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
The primary objective is to estimate the efficacy of experimental treatment with the anti-PD-1 antibody cemiplimab (REGN2810) in combination with simultaneous or subsequent radiotherapy (RT) in early-stage favorable classical…
- Trial name
- NCT04373083
- Testing
- Cemiplimab, Involved-site radiotherapy (IS-RT)
- Sponsor
- Regeneron Pharmaceuticals
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Multiple Myeloma
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
This is a phase I, first in human, single arm, open label study that will assess safety, tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule by patients with relapsed and refractory…
- Trial name
- NCT05271682
- Testing
- FHND6091
- Where
- 6 sites in China
- Volunteers
- 40 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Lymphoma
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy…
- Trial name
- NCT02038946
- Testing
- Nivolumab
- Where
- 45 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Large B Cell Lymphoma
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT07368270
- Testing
- Anti-PD1 armored CD19 CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
- Conditions
- Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
- Trial name
- NCT07613723
- Testing
- ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Zelluna Immunotherapy AS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.